DavidAllenReardonMD

Oncology • Boston, MA

Hematologic Oncology, Neuro-Oncology

Clinical Director, Center for Neuro-Oncology Dana-Farber Cancer Institute Boston, MA

Join to view full profile

Dr. Reardon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Reardon's full profile

Already have an account?

Office
450 Brookline Avenue, G460f
Center For Neuro-Oncology, Dana-Farber Cancer Institute
Boston, MA 02215
Phone+1 617-632-6172

Fax+1 617-632-4773
Is this information wrong?

Education & Training

University of Michigan Health SystemFellowship, Pediatric Hematology/Oncology, 1990 - 1993
Johns Hopkins UniversityResidency, Pediatrics, 1987 - 1989
Tufts University School of MedicineClass of 1986

Certifications & Licensure

FL State Medical License 2022 - Present
MA State Medical License 2011 - 2025
CT State Medical License 2022 - 2024
NC State Medical License 2000 - 2011
ME State Medical License Active through 2000
TN State Medical License 1995 - 2000
MI State Medical License 1989 - 1998

Clinical Trials

Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor) Start of enrollment: 2004 Oct 13
Completed
Phase 2
Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM) Start of enrollment: 2004 Jan 01
Completed
Phase 1, Phase 2
Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma Start of enrollment: 2004 Jul 01
Completed
Phase 1
Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma Start of enrollment: 2005 May 01
Completed
Phase 2
Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma Start of enrollment: 2005 Jul 01
Completed
Phase 1
AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme Start of enrollment: 2006 Oct 01
Unknown status
Phase 1, Phase 2
Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM Start of enrollment: 2007 Sep 01
Completed
Phase 2
Ph I SU011248 + Irinotecan in Treatment of Pts w MG Start of enrollment: 2008 Mar 01
Completed
Phase 1
Ph II Bevacizumab + Etoposide for Pts w Recurrent MG Start of enrollment: 2007 Mar 01
Completed
Phase 2
Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas Start of enrollment: 2005 Jan 01
Completed
Phase 1
Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM Start of enrollment: 2005 Feb 01
Completed
Phase 1
Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan Start of enrollment: 2008 Apr 01
Completed
Phase 2
Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma Start of enrollment: 2002 Oct 01
Completed
Phase 2
Glioblastoma Multiforme (GBM) Locoregional Agent Survival Study - Anti-tenascin Radiolabeled Antibody Therapy Start of enrollment: 2008 Jun 01
Terminated
Phase 3
Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + Temozolomide Start of enrollment: 2005 Nov 01
Completed
Phase 2
Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG) Start of enrollment: 2007 Feb 01
Completed
Phase 2
Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme Start of enrollment: 2007 Apr 01
Completed
Phase 2
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Start of enrollment: 2009 Jul 10
Completed
Phase 1, Phase 2
Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme Start of enrollment: 2009 May 01
Unknown status
Phase 2
A Panobinostat Presurgery Start of enrollment: 2010 Apr 01
Withdrawn
Phase 2
Amgen 386 for Recurrent Glioblastoma Start of enrollment: 2010 Dec 01
Completed
Phase 1, Phase 2
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma Start of enrollment: 2011 Dec 01
Completed
Phase 2
A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2013 Jul 18
Completed
Phase 1, Phase 2
A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients Start of enrollment: 2014 Feb 07
Active, not recruiting
Phase 3
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme Start of enrollment: 2014 May 01
Completed
Phase 1, Phase 2
A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma Start of enrollment: 2015 Jan 01
Completed
Phase 1, Phase 2
An Open-Label Phase II Study of Nivolumab in Adult Participants With Progessive/ Recurrent Meningioma Start of enrollment: 2016 Mar 01
Recruiting
Phase 2
Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM Start of enrollment: 2018 May 21
Active, not recruiting
Phase 2
Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma Start of enrollment: 2018 Sep 28
Active, not recruiting
Phase 2
ASP8374 + Cemiplimab in Recurrent Glioma Start of enrollment: 2022 Mar 09
Active, not recruiting
Phase 1
First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma Start of enrollment: 2020 Jul 13
Active, not recruiting
Phase 1, Phase 2
Roles: Contact
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM Start of enrollment: 2014 Nov 01
Recruiting
Phase 1
Roles: Principal Investigator, Contact
SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE) Start of enrollment: 2021 Nov 18
Active, not recruiting
Phase 2
Roles: Contact
Study of DSP-0390 in Patients With Recurrent High-Grade Glioma Start of enrollment: 2021 Sep 08
Active, not recruiting
Early Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Auto-segmentation of Adult-Type Diffuse Gliomas: Comparison of Transfer Learning-Based Convolutional Neural Network Model vs. Radiologists.
Qi Wan, Jisoo Kim, Clifford Lindsay, Xin Chen, Jing Li, J Bryan Iorgulescu, Raymond Y Huang, Chenxi Zhang, David Reardon, Geoffrey S Young, Lei Qin> ;Journal of Imaging Informatics in Medicine. 2024 Feb 21
2 citations
Re-irradiation of recurrent IDH-wildtype glioblastoma in the bevacizumab and immunotherapy era: Target delineation, outcomes and patterns of recurrence.
Christ, S., Youssef, G., Shi, D., McFaline-Figueroa, J., Hertler, C., Andratschke, N., Weller, M., Guckenberger, M., Tanguturi, S., Cagney, D., Chukwueke, U., Lee, E.,...> ;Clinical and Translational Radiation Oncology. 2024 Jan 1
Lessons learned from phase 3 trials of immunotherapy for glioblastoma: Time for longitudinal sampling?
Ethan Chen, Alexander L Ling, David A Reardon, E Antonio Chiocca> ;Neuro-Oncology. 2024 Feb 2
11 citations
Clinical trial links oncolytic immunoactivation to survival in glioblastoma.
Alexander L Ling, Isaac H Solomon, Ana Montalvo Landivar, Hiroshi Nakashima, Jared K Woods, Andres Santos, Nafisa Masud, Geoffrey Fell, Xiaokui Mo, Ayse S Yilmaz, Jame...> ;Nature. 2023 Nov 1
7 citations
RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults.
Patrick Y Wen, Martin van den Bent, Gilbert Youssef, Timothy F Cloughesy, Benjamin M Ellingson, Michael Weller, Evanthia Galanis, Daniel P Barboriak, John de Groot, Ma...> ;Journal of Clinical Oncology. 2023 Nov 20
3 citations
Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian A...
Rifaquat Rahman, Lorenzo Trippa, Eudocia Q Lee, Isabel Arrillaga-Romany, Geoffrey Fell, Mehdi Touat, Christine McCluskey, Jennifer Wiley, Sarah Gaffey, Jan Drappatz, M...> ;Journal of Clinical Oncology. 2023 Dec 20
2 citations
Glioma genetic profiles associated with electrophysiologic hyperexcitability.
Steven Tobochnik, Maria Kristina C Dorotan, Hia S Ghosh, Emily Lapinskas, Jayne Vogelzang, David A Reardon, Keith L Ligon, Wenya Linda Bi, Stelios M Smirnakis, Jong Wo...> ;Neuro-Oncology. 2024 Feb 2
12 citations
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.
Shubham Pant, Martin Schuler, Gopa Iyer, Olaf Witt, Toshihiko Doi, Shukui Qin, Josep Tabernero, David A Reardon, Christophe Massard, Anna Minchom, Iwona Lugowska, Omar...> ;The Lancet. Oncology. 2023 Aug 1
Metastatic pituitary tumors: an institutional case series.
Alexander G Yearley, Eric J Chalif, Saksham Gupta, Joshua I Chalif, Joshua D Bernstock, Noah Nawabi, Omar Arnaout, Timothy R Smith, David A Reardon, Edward R Laws> ;Pituitary. 2023 Oct 1
A new era for glioma therapy - targeting mutant IDH.
David A Reardon, Daniel P Cahill> ;Nature Reviews. Clinical Oncology. 2023 Nov 1
15 citations
BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas.
Priscilla K Brastianos, Erin Twohy, Susan Geyer, Elizabeth R Gerstner, Timothy J Kaufmann, Shervin Tabrizi, Brian Kabat, Julia Thierauf, Michael W Ruff, Daniela A Bota...> ;The New England Journal of Medicine. 2023 Jul 13
2 citations
Evaluating hematologic parameters in newly diagnosed and recurrent glioblastoma: Prognostic utility and clinical trial implications of myelosuppression.
Davy Deng, Lubna Hammoudeh, Gilbert Youssef, Yu-Hui Chen, Kee-Young Shin, Mary Jane Lim-Fat, Jose Ricardo McFaline-Figueroa, Ugonma N Chukwueke, Shyam Tanguturi, David...> ;Neuro-Oncology Advances. 2023 Jul 8
3 citations
Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients.
K Ina Ly, Leland G Richardson, Mofei Liu, Alona Muzikansky, Jonathan Cardona, Kevin Lou, Andrew L Beers, Ken Chang, James M Brown, Xiaoyue Ma, David A Reardon, Isabel ...> ;Clinical Cancer Research. 2023 Aug 15
7 citations
Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419).
Caroline Hertler, Jörg Felsberg, Dorothee Gramatzki, Emilie Le Rhun, Jennifer Clarke, Riccardo Soffietti, Wolfgang Wick, Olivier Chinot, François Ducray, Patrick Roth,...> ;European Journal of Cancer. 2023 Aug 1
An expanded role for surgery in grade 3 1p/19q co-deleted oligodendroglioma.
Saksham Gupta, Noah L Nawabi, Siva Emani, Lila Medeiros, Joshua D Bernstock, Julia Duvall, Patrick Ng, Timothy R Smith, Patrick Y Wen, David A Reardon, Omar Arnaout> ;Neuro-Oncology Advances. 2023 Apr 21
5 citations
Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint Inhibitors.
Joseph Toker, J Bryan Iorgulescu, Alexander L Ling, Genaro R Villa, Josephina A M A Gadet, Laxmi Parida, Gad Getz, Catherine J Wu, David A Reardon, E Antonio Chiocca, ...> ;Clinical Cancer Research. 2023 Jun 13
8 citations
Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology i...
Gilbert Youssef, Rifaquat Rahman, Camden Bay, Wei Wang, Mary Jane Lim-Fat, Omar Arnaout, Wenya Linda Bi, Daniel N Cagney, Yuh-Shin Chang, Timothy F Cloughesy, Matthew ...> ;Journal of Clinical Oncology. 2023 Jun 10
1 citations
The Blood-Brain Barrier: Implications for Experimental Cancer Therapeutics.
Agar, N., Straehla, J., Reardon, D., Wen, P.> ;Annual Review of Cancer Biology. 2023 Apr 1
1 citations
Glioma genetic profiles associated with electrophysiologic hyperexcitability.
Steven Tobochnik, Maria Kristina C Dorotan, Hia S Ghosh, Emily Lapinskas, Jayne Vogelzang, David A Reardon, Keith L Ligon, Wenya Linda Bi, Stelios M Smirnakis, Jong Wo...> ;Medrxiv. 2023 Feb 24
2 citations
ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma.
Anne-Florence Blandin, Ross Giglio, Maya Srikanth Graham, Guadalupe Garcia, Seth Malinowski, Jared K Woods, Shakti Ramkissoon, Lori Ramkissoon, Frank Dubois, Kathleen ...> ;Clinical Cancer Research. 2023 Jul 14
13 citations
Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models.
Meenal Datta, Sampurna Chatterjee, Elizabeth M Perez, Simon Gritsch, Sylvie Roberge, Mark Duquette, Ivy X Chen, Kamila Naxerova, Ashwin S Kumar, Mitrajit Ghosh, Kyrre ...> ;Proceedings of the National Academy of Sciences of the United States of America. 2023 Feb 7
Antigen presentation deficiency, mesenchymal differentiation, and resistance to immunotherapy in the murine syngeneic CT2A tumor model.
J Bryan Iorgulescu, Neil Ruthen, Ryuhjin Ahn, Eleni Panagioti, Prafulla C Gokhale, Martha Neagu, Maria C Speranza, Benjamin K Eschle, Kara M Soroko, Raziye Piranlioglu...> ;Frontiers in Immunology. 2023 Jan 1
1 citations
PARP inhibition utilized in combination therapy with Olaparib-Temozolomide to achieve disease stabilization in a rare case of BRCA1-mutant, metastatic myxopapillary ep...
Preethika Mahalingam, Sam Smith, Juanita Lopez, Rajaei K Sharma, Thomas Millard, Khin Thway, Cyril Fisher, David A Reardon, Robin Jones, Andrew G Nicholson, David Cunn...> ;Rare Tumors. 2023 Jan 1
20 citations
Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma.
Manmeet S Ahluwalia, David A Reardon, Ajay P Abad, William T Curry, Eric T Wong, Sheila A Figel, Laszlo L Mechtler, David M Peereboom, Alan D Hutson, Henry G Withers, ...> ;Journal of Clinical Oncology. 2023 Mar 1
7 citations
Immunotherapy approaches for adult glioma: knowledge gained from recent clinical trials.
Brian M Andersen, David A Reardon> ;Current Opinion in Neurology. 2022 Dec 1
Join now to see all

Journal Articles

Socioeconomic Disparities Associated with MGMT Promoter Methylation Testing for Patients with Glioblastoma
David Reardon, MD, JAMA Oncology
Socioeconomic Disparities Associated with MGMT Promoter Methylation Testing for Patients with Glioblastoma
David Reardon, MD, JAMA Oncology
Effect of Nivolumab vs Bevacizumab in Patients with Recurrent Glioblastoma
David A Reardon, Antonio Omuro, Joachim Baehring, Surasak Phuphanich, Solmaz Sahebjam, JAMA Oncology

Lectures

Concepts for Immunotherapies in Gliomas
2019 ASCO Annual Meeting - 6/1/2019

Authored Content

Effect of Nivolumab vs Bevacizumab in Patients with Recurrent GlioblastomaMay 2020
Effect of Nivolumab vs Bevacizumab in Patients with Recurrent GlioblastomaMay 2020
Effect of Nivolumab vs Bevacizumab in Patients with Recurrent GlioblastomaMay 2020

Press Mentions

In Mouse Study, New Gel Therapy Stops Dangerous Brain TumorsApril 26th, 2023
Vivacitas Oncology Appoints Harvard Professor of Medicine Dr. David Reardon, MD to the Company's Neuro-Oncology Medical Advisory BoardMarch 21st, 2022
A Revolutionary Clinical Trial Is Testing Customized Vaccines That Target Cancerous TumorsNovember 4th, 2021
Join now to see all

Grant Support

Translational Clinical Trials For Primary CNS TumorsNational Institute Of Neurological Disorders And Stroke2009–2012
Core--Phase I/II Clinical TrialsNational Cancer Institute2007–2008
Translational Clinical Trials In Neuro-OncologyNational Institute Of Neurological Disorders And Stroke2004–2008
Core-3-Phase I/II Clinical TrialsNational Cancer Institute2004–2006
Phase II Study Of 44gy From 131i-81c6 For CNS TumorsNational Cancer Institute2003–2004
Core--Phase I / II Clinical Trials CoreNational Cancer Institute2002